Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 14
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
KRAS G12D
NSCLC · Immune Checkpoint Inhibitor
KRAS G12D is flagged as trial selection rising because public trials show inclusion required evidence in 16 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 14
Common snippets: MET exon 14 skipping | KRAS G12C | KRAS G12C
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03225664 | https://clinicaltrials.gov/study/NCT07111520 | https://clinicaltrials.gov/study/NCT07285434 | https://clinicaltrials.gov/study/NCT06119581 | https://clinicaltrials.gov/study/NCT03948763 | https://clinicaltrials.gov/study/NCT07190248 | https://clinicaltrials.gov/study/NCT05789082 | https://clinicaltrials.gov/study/NCT06890598 | https://clinicaltrials.gov/study/NCT06345729 | https://clinicaltrials.gov/study/NCT07639242 | https://clinicaltrials.gov/study/NCT07252739 | https://clinicaltrials.gov/study/NCT04585035 | https://clinicaltrials.gov/study/NCT06447662 | https://clinicaltrials.gov/study/NCT02955290 | https://clinicaltrials.gov/study/NCT05061017 | https://clinicaltrials.gov/study/NCT06908993